Acceleron, Shire Ink Collaboration | September 20, 2010 Issue - Vol. 88 Issue 38 | Chemical & Engineering News
Volume 88 Issue 38 | p. 14 | Concentrates
Issue Date: September 20, 2010

Acceleron, Shire Ink Collaboration

Department: Business
Keywords: drug development, collaboration

Acceleron Pharma and Shire have formed a joint development and commercialization agreement under which Shire will obtain rights outside the U.S. to a range of Acceleron molecules targeting activin receptor type IIB pathway, which helps regulate skeletal muscle growth. The collaboration will initially investigate ACE-031, currently in Phase II clinical trials for patients with Duchenne muscular dystrophy (DMD). Shire will make an up-front payment of $45 million to Acceleron, as well as possible milestone payments.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment